ID   PPM1K_HUMAN             Reviewed;         372 AA.
AC   Q8N3J5; B2RAZ1; Q05CT5; Q49AB5; Q4W5E6; Q56AN8; Q8IUZ7; Q8IXG7;
AC   Q8ND70; Q96NT4;
DT   20-FEB-2007, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-2002, sequence version 1.
DT   22-JUL-2015, entry version 111.
DE   RecName: Full=Protein phosphatase 1K, mitochondrial;
DE            EC=3.1.3.16;
DE   AltName: Full=PP2C domain-containing protein phosphatase 1K;
DE   AltName: Full=PP2C-like mitochondrial protein;
DE   AltName: Full=PP2C-type mitochondrial phosphoprotein phosphatase;
DE            Short=PTMP;
DE   AltName: Full=Protein phosphatase 2C isoform kappa;
DE            Short=PP2C-kappa;
DE   Flags: Precursor;
GN   Name=PPM1K; Synonyms=PP2CM;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, SUBCELLULAR
RP   LOCATION, TRANSIT PEPTIDE CLEAVAGE SITE, AND MUTAGENESIS OF ASP-298.
RX   PubMed=17374715; DOI=10.1101/gad.1499107;
RA   Lu G., Ren S., Korge P., Choi J., Dong Y., Weiss J., Koehler C.,
RA   Chen J.-N., Wang Y.;
RT   "A novel mitochondrial matrix serine/threonine protein phosphatase
RT   regulates the mitochondria permeability transition pore and is
RT   essential for cellular survival and development.";
RL   Genes Dev. 21:784-796(2007).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2).
RA   Mao Y., Xie Y., Dai J.;
RT   "Cloning and characterization of a novel human PP2C gene from fetal
RT   brain.";
RL   Submitted (OCT-2002) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), SUBCELLULAR LOCATION, AND
RP   BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=17336929; DOI=10.1016/j.bbrc.2007.02.108;
RA   Joshi M.A., Jeoung N.H., Popov K.M., Harris R.A.;
RT   "Identification of a novel PP2C-type mitochondrial phosphatase.";
RL   Biochem. Biophys. Res. Commun. 356:38-44(2007).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RA   Xu J., Stagliano N., Deponte J. III, Rodrigue-Way A., Golden S.,
RA   Katz S., Jeyaseelan R., Donoghue M., Meyers R., Gottfried S.,
RA   Wysong D., McGovern K., Pollman M., Breitbart R.E., Acton S.;
RT   "Protein phosphatase 2C kappa is upregulated in heart failure and
RT   attenuates agonist-induced cardiomyocyte hypertrophy.";
RL   Submitted (OCT-2003) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Cerebellum, and Testis;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Amygdala, and Lymph node;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H.,
RA   Heubner D., Hoerlein A., Michel G., Wedler H., Koehrer K.,
RA   Ottenwaelder B., Poustka A., Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H.,
RA   Minx P., Wagner-McPherson C., Layman D., Wylie K., Sekhon M.,
RA   Becker M.C., Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E.,
RA   Kremitzki C., Oddy L., Du H., Sun H., Bradshaw-Cordum H., Ali J.,
RA   Carter J., Cordes M., Harris A., Isak A., van Brunt A., Nguyen C.,
RA   Du F., Courtney L., Kalicki J., Ozersky P., Abbott S., Armstrong J.,
RA   Belter E.A., Caruso L., Cedroni M., Cotton M., Davidson T., Desai A.,
RA   Elliott G., Erb T., Fronick C., Gaige T., Haakenson W., Haglund K.,
RA   Holmes A., Harkins R., Kim K., Kruchowski S.S., Strong C.M.,
RA   Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N.,
RA   Swearengen-Shahid S., Snider J., Strong J.T., Thompson J., Yoakum M.,
RA   Leonard S., Pearman C., Trani L., Radionenko M., Waligorski J.E.,
RA   Wang C., Rock S.M., Tin-Wollam A.-M., Maupin R., Latreille P.,
RA   Wendl M.C., Yang S.-P., Pohl C., Wallis J.W., Spieth J., Bieri T.A.,
RA   Berkowicz N., Nelson J.O., Osborne J., Ding L., Meyer R., Sabo A.,
RA   Shotland Y., Sinha P., Wohldmann P.E., Cook L.L., Hickenbotham M.T.,
RA   Eldred J., Williams D., Jones T.A., She X., Ciccarelli F.D.,
RA   Izaurralde E., Taylor J., Schmutz J., Myers R.M., Cox D.R., Huang X.,
RA   McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D.,
RA   Waterston R.H., Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2
RT   and 4.";
RL   Nature 434:724-731(2005).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 3), AND VARIANT
RP   LYS-94.
RC   TISSUE=Pancreas, and Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [10]
RP   INVOLVEMENT IN MSUDMV.
RX   PubMed=23086801; DOI=10.1002/humu.22242;
RA   Oyarzabal A., Martinez-Pardo M., Merinero B., Navarrete R.,
RA   Desviat L.R., Ugarte M., Rodriguez-Pombo P.;
RT   "A novel regulatory defect in the branched-chain alpha-keto acid
RT   dehydrogenase complex due to a mutation in the PPM1K gene causes a
RT   mild variant phenotype of maple syrup urine disease.";
RL   Hum. Mutat. 34:355-362(2013).
RN   [11]
RP   X-RAY CRYSTALLOGRAPHY (2.25 ANGSTROMS) OF 89-351, AND
RP   MAGNESIUM-BINDING.
RX   PubMed=18058037; DOI=10.1007/s10969-007-9036-1;
RA   Almo S.C., Bonanno J.B., Sauder J.M., Emtage S., Dilorenzo T.P.,
RA   Malashkevich V., Wasserman S.R., Swaminathan S., Eswaramoorthy S.,
RA   Agarwal R., Kumaran D., Madegowda M., Ragumani S., Patskovsky Y.,
RA   Alvarado J., Ramagopal U.A., Faber-Barata J., Chance M.R., Sali A.,
RA   Fiser A., Zhang Z.Y., Lawrence D.S., Burley S.K.;
RT   "Structural genomics of protein phosphatases.";
RL   J. Struct. Funct. Genomics 8:121-140(2007).
RN   [12]
RP   VARIANT HIS-26.
RX   PubMed=23200863; DOI=10.1016/j.ajhg.2012.10.024;
RA   Charlesworth G., Plagnol V., Holmstroem K.M., Bras J., Sheerin U.M.,
RA   Preza E., Rubio-Agusti I., Ryten M., Schneider S.A., Stamelou M.,
RA   Trabzuni D., Abramov A.Y., Bhatia K.P., Wood N.W.;
RT   "Mutations in ANO3 cause dominant craniocervical dystonia: ion channel
RT   implicated in pathogenesis.";
RL   Am. J. Hum. Genet. 91:1041-1050(2012).
CC   -!- FUNCTION: Regulates the mitochondrial permeability transition pore
CC       and is essential for cellular survival and development.
CC       {ECO:0000269|PubMed:17374715}.
CC   -!- CATALYTIC ACTIVITY: [a protein]-serine/threonine phosphate + H(2)O
CC       = [a protein]-serine/threonine + phosphate.
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC       Name=Mn(2+); Xref=ChEBI:CHEBI:29035;
CC       Note=Binds 1 Mg(2+) or Mn(2+) ion per subunit.;
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=10.7 mM for p-nitrophenylphosphate
CC         {ECO:0000269|PubMed:17336929};
CC         Vmax=3.6 umol/min/mg enzyme toward p-nitrophenylphosphate (at 30
CC         degrees Celsius) {ECO:0000269|PubMed:17336929};
CC         Vmax=4 nmol/min/mg enzyme toward branched-chain alpha-ketoacid
CC         dehydrogenase complex (at 37 degrees Celsius)
CC         {ECO:0000269|PubMed:17336929};
CC         Note=Half maximal activity toward p-nitrophenylphosphate
CC         achieved with 3.7 mM of manganese ions.;
CC   -!- INTERACTION:
CC       Q13490:BIRC2; NbExp=3; IntAct=EBI-3923368, EBI-514538;
CC   -!- SUBCELLULAR LOCATION: Mitochondrion matrix
CC       {ECO:0000269|PubMed:17336929, ECO:0000269|PubMed:17374715}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=Q8N3J5-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q8N3J5-2; Sequence=VSP_023158, VSP_023159;
CC       Name=3;
CC         IsoId=Q8N3J5-3; Sequence=VSP_023156, VSP_023157;
CC   -!- DISEASE: Maple syrup urine disease, mild variant (MSUDMV)
CC       [MIM:615135]: A mild form of maple syrup urine disease, a
CC       metabolic disorder due to an enzyme defect in the catabolic
CC       pathway of the branched-chain amino acids leucine, isoleucine, and
CC       valine. Accumulation of these 3 amino acids and their
CC       corresponding keto acids leads to encephalopathy and progressive
CC       neurodegeneration. Clinical features include mental and physical
CC       retardation, feeding problems, and a maple syrup odor to the
CC       urine. The keto acids of the branched-chain amino acids are
CC       present in the urine. If untreated, maple syrup urine disease can
CC       lead to seizures, coma, and death. The disease is often classified
CC       by its pattern of signs and symptoms. The most common and severe
CC       form of the disease is the classic type, which becomes apparent
CC       soon after birth. Variant forms of the disorder become apparent
CC       later in infancy or childhood and are typically milder, but they
CC       still involve developmental delay and other medical problems if
CC       not treated. MSUDMV is characterized by increased plasma levels of
CC       branched-chain amino acids (BCAA) apparent at birth. Treatment
CC       with a low-protein diet free of BCAA can result in normal
CC       psychomotor development and lack of metabolic episodes.
CC       {ECO:0000269|PubMed:23086801}. Note=The gene represented in this
CC       entry is involved in disease pathogenesis.
CC   -!- SIMILARITY: Belongs to the PP2C family. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 1 PPM-type phosphatase domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU01082}.
CC   -!- CAUTION: PubMed:18058037 has crystallized PPM1K in the presence of
CC       magnesium ions. However, PubMed:17336929 reported that no activity
CC       toward p-nitrophenylphosphate was seen in the absence of manganese
CC       ions and magnesium could not substitute for manganese.
CC       {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AY157615; AAO17296.1; -; mRNA.
DR   EMBL; AF351614; AAN76514.1; -; mRNA.
DR   EMBL; AY994097; AAX77016.1; -; mRNA.
DR   EMBL; AY435431; AAR06213.1; -; mRNA.
DR   EMBL; AK054678; BAB70790.1; -; mRNA.
DR   EMBL; AK314417; BAG37038.1; -; mRNA.
DR   EMBL; AL834167; CAD38869.2; -; mRNA.
DR   EMBL; AL834271; CAD38946.1; -; mRNA.
DR   EMBL; AC107067; AAY41021.1; -; Genomic_DNA.
DR   EMBL; AC108213; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471057; EAX06016.1; -; Genomic_DNA.
DR   EMBL; BC020850; AAH20850.1; ALT_TERM; mRNA.
DR   EMBL; BC037552; AAH37552.1; -; mRNA.
DR   EMBL; BC041350; AAH41350.1; -; mRNA.
DR   CCDS; CCDS3629.1; -. [Q8N3J5-1]
DR   RefSeq; NP_689755.3; NM_152542.4. [Q8N3J5-1]
DR   RefSeq; XP_006714174.1; XM_006714111.2. [Q8N3J5-1]
DR   UniGene; Hs.43744; -.
DR   PDB; 2IQ1; X-ray; 2.25 A; A=89-351.
DR   PDB; 4DA1; X-ray; 2.38 A; A=84-360.
DR   PDBsum; 2IQ1; -.
DR   PDBsum; 4DA1; -.
DR   ProteinModelPortal; Q8N3J5; -.
DR   SMR; Q8N3J5; 90-349.
DR   BioGrid; 127472; 5.
DR   IntAct; Q8N3J5; 2.
DR   MINT; MINT-4725175; -.
DR   STRING; 9606.ENSP00000295908; -.
DR   DEPOD; Q8N3J5; -.
DR   PhosphoSite; Q8N3J5; -.
DR   DMDM; 74750962; -.
DR   PaxDb; Q8N3J5; -.
DR   PRIDE; Q8N3J5; -.
DR   DNASU; 152926; -.
DR   Ensembl; ENST00000608933; ENSP00000477341; ENSG00000163644.
DR   GeneID; 152926; -.
DR   KEGG; hsa:152926; -.
DR   UCSC; uc003hrm.5; human. [Q8N3J5-1]
DR   UCSC; uc003hrn.4; human. [Q8N3J5-2]
DR   CTD; 152926; -.
DR   GeneCards; GC04M089178; -.
DR   HGNC; HGNC:25415; PPM1K.
DR   HPA; HPA020066; -.
DR   HPA; HPA020862; -.
DR   HPA; HPA023891; -.
DR   MIM; 611065; gene.
DR   MIM; 615135; phenotype.
DR   neXtProt; NX_Q8N3J5; -.
DR   Orphanet; 268162; Intermediate maple syrup urine disease.
DR   PharmGKB; PA134912083; -.
DR   eggNOG; COG0631; -.
DR   GeneTree; ENSGT00740000114971; -.
DR   HOVERGEN; HBG096199; -.
DR   InParanoid; Q8N3J5; -.
DR   KO; K17505; -.
DR   OMA; IKLYHAD; -.
DR   OrthoDB; EOG7992QN; -.
DR   PhylomeDB; Q8N3J5; -.
DR   TreeFam; TF354344; -.
DR   BRENDA; 3.1.3.16; 2681.
DR   ChiTaRS; PPM1K; human.
DR   EvolutionaryTrace; Q8N3J5; -.
DR   GeneWiki; PPM1K; -.
DR   GenomeRNAi; 152926; -.
DR   NextBio; 87055; -.
DR   PRO; PR:Q8N3J5; -.
DR   Proteomes; UP000005640; Chromosome 4.
DR   Bgee; Q8N3J5; -.
DR   ExpressionAtlas; Q8N3J5; baseline and differential.
DR   Genevisible; Q8N3J5; HS.
DR   GO; GO:0005759; C:mitochondrial matrix; IEA:UniProtKB-SubCell.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0004722; F:protein serine/threonine phosphatase activity; IEA:InterPro.
DR   GO; GO:0006470; P:protein dephosphorylation; IEA:InterPro.
DR   Gene3D; 3.60.40.10; -; 1.
DR   InterPro; IPR015655; PP2C.
DR   InterPro; IPR000222; PP2C_BS.
DR   InterPro; IPR001932; PPM-type_phosphatase_dom.
DR   PANTHER; PTHR13832; PTHR13832; 1.
DR   Pfam; PF00481; PP2C; 1.
DR   SMART; SM00331; PP2C_SIG; 1.
DR   SMART; SM00332; PP2Cc; 1.
DR   SUPFAM; SSF81606; SSF81606; 1.
DR   PROSITE; PS01032; PPM_1; 1.
DR   PROSITE; PS51746; PPM_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Complete proteome; Hydrolase;
KW   Magnesium; Manganese; Metal-binding; Mitochondrion; Phosphoprotein;
KW   Polymorphism; Protein phosphatase; Reference proteome;
KW   Transit peptide.
FT   TRANSIT       1     29       Mitochondrion.
FT                                {ECO:0000269|PubMed:17374715}.
FT   CHAIN        30    372       Protein phosphatase 1K, mitochondrial.
FT                                /FTId=PRO_0000278208.
FT   DOMAIN       94    346       PPM-type phosphatase.
FT                                {ECO:0000255|PROSITE-ProRule:PRU01082}.
FT   METAL       127    127       Magnesium.
FT   METAL       128    128       Magnesium; via carbonyl oxygen.
FT   METAL       337    337       Magnesium.
FT   MOD_RES     248    248       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q8BXN7}.
FT   VAR_SEQ     148    150       DLL -> YVQ (in isoform 3).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_023156.
FT   VAR_SEQ     151    372       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_023157.
FT   VAR_SEQ     181    233       ATLLTSGTTATVALLRDGIELVVASVGDSRAILCRKGKPMK
FT                                LTIDHTPERKDE -> ENCAWSAALDLEPVDTICGASVERE
FT                                ICLILSQVKESSGSYPGLREGSHISLSH (in isoform
FT                                2). {ECO:0000303|Ref.2}.
FT                                /FTId=VSP_023158.
FT   VAR_SEQ     234    372       Missing (in isoform 2).
FT                                {ECO:0000303|Ref.2}.
FT                                /FTId=VSP_023159.
FT   VARIANT      26     26       R -> H. {ECO:0000269|PubMed:23200863}.
FT                                /FTId=VAR_069736.
FT   VARIANT      94     94       N -> K (in dbSNP:rs17853762).
FT                                {ECO:0000269|PubMed:15489334}.
FT                                /FTId=VAR_030691.
FT   VARIANT     321    321       E -> K (in dbSNP:rs35523553).
FT                                /FTId=VAR_050621.
FT   MUTAGEN     298    298       D->A: Loss of activity.
FT                                {ECO:0000269|PubMed:17374715}.
FT   CONFLICT     17     17       V -> A (in Ref. 3; AAX77016).
FT                                {ECO:0000305}.
FT   CONFLICT    194    194       L -> I (in Ref. 3; AAX77016).
FT                                {ECO:0000305}.
FT   CONFLICT    211    211       A -> V (in Ref. 9; AAH20850).
FT                                {ECO:0000305}.
FT   CONFLICT    264    264       I -> V (in Ref. 5; BAB70790).
FT                                {ECO:0000305}.
FT   HELIX        92     94       {ECO:0000244|PDB:2IQ1}.
FT   STRAND       96    100       {ECO:0000244|PDB:2IQ1}.
FT   STRAND      103    106       {ECO:0000244|PDB:2IQ1}.
FT   STRAND      109    115       {ECO:0000244|PDB:2IQ1}.
FT   STRAND      117    131       {ECO:0000244|PDB:2IQ1}.
FT   HELIX       133    149       {ECO:0000244|PDB:2IQ1}.
FT   TURN        150    152       {ECO:0000244|PDB:2IQ1}.
FT   HELIX       156    176       {ECO:0000244|PDB:2IQ1}.
FT   HELIX       183    185       {ECO:0000244|PDB:2IQ1}.
FT   STRAND      190    196       {ECO:0000244|PDB:2IQ1}.
FT   TURN        197    199       {ECO:0000244|PDB:2IQ1}.
FT   STRAND      200    208       {ECO:0000244|PDB:2IQ1}.
FT   STRAND      210    215       {ECO:0000244|PDB:2IQ1}.
FT   STRAND      218    221       {ECO:0000244|PDB:2IQ1}.
FT   HELIX       231    239       {ECO:0000244|PDB:2IQ1}.
FT   STRAND      244    246       {ECO:0000244|PDB:2IQ1}.
FT   STRAND      252    254       {ECO:0000244|PDB:2IQ1}.
FT   TURN        255    257       {ECO:0000244|PDB:2IQ1}.
FT   HELIX       267    269       {ECO:0000244|PDB:2IQ1}.
FT   TURN        270    273       {ECO:0000244|PDB:2IQ1}.
FT   STRAND      279    284       {ECO:0000244|PDB:2IQ1}.
FT   TURN        287    289       {ECO:0000244|PDB:2IQ1}.
FT   STRAND      290    296       {ECO:0000244|PDB:2IQ1}.
FT   HELIX       298    301       {ECO:0000244|PDB:2IQ1}.
FT   HELIX       306    314       {ECO:0000244|PDB:2IQ1}.
FT   STRAND      316    318       {ECO:0000244|PDB:2IQ1}.
FT   HELIX       319    332       {ECO:0000244|PDB:2IQ1}.
FT   STRAND      339    345       {ECO:0000244|PDB:2IQ1}.
SQ   SEQUENCE   372 AA;  40997 MW;  9DD37EEC0EAD3313 CRC64;
     MSTAALITLV RSGGNQVRRR VLLSSRLLQD DRRVTPTCHS STSEPRCSRF DPDGSGSPAT
     WDNFGIWDNR IDEPILLPPS IKYGKPIPKI SLENVGCASQ IGKRKENEDR FDFAQLTDEV
     LYFAVYDGHG GPAAADFCHT HMEKCIMDLL PKEKNLETLL TLAFLEIDKA FSSHARLSAD
     ATLLTSGTTA TVALLRDGIE LVVASVGDSR AILCRKGKPM KLTIDHTPER KDEKERIKKC
     GGFVAWNSLG QPHVNGRLAM TRSIGDLDLK TSGVIAEPET KRIKLHHADD SFLVLTTDGI
     NFMVNSQEIC DFVNQCHDPN EAAHAVTEQA IQYGTEDNST AVVVPFGAWG KYKNSEINFS
     FSRSFASSGR WA
//
